Mutations in the CBS gene (MIM# 613381) cause classical homocystinuria (Hcu, MIM# 236200), an autosomal recessive disease characterized by severe hyperhomocysteinemia and homocystinuria, decreased plasma levels of cysteine and, often, hypermethioninemia. At the clinical level, classical homocystinuria mainly affects the eye, the skeleton, the vascular system and the central nervous system (CNS). Symptoms usually include ectopia lentis, osteoporosis, scoliosis, Marfanoid features, premature arteriosclerosis, thromboembolism and mental retardation (Mudd, et al., 1985) . Age of onset and disease severity are highly variable, ranging from dramatically affected children to asymptomatic adults (Magner, et al., 2011; Skovby, et al., 2010; Walter, et al., 1998; Yap and Naughten, 1998) . Treatments that lower tHcy, such as B-vitamins, dietary methionine restriction, and betaine supplementation, can significantly reduce the incidence of vascular events (the main cause of death in these patients) and improve the neurological problems (Wilcken and Wilcken, 1997; Yap, et al., 2001; Yap and Naughten, 1998) . Homocystinuria is a rare disease with variable incidence. While the worldwide incidence is estimated as 1/344000 born alive (Mudd, et al., 1995) , in Qatar it is 1/3124 (El-Said, et al., 2006) and in Japan 1/800 000 (Mudd, et al., 1995) . In Northern Europe the incidence may be of 1/20500 to 1/6400, as estimated from the high F o r P e e r R e v i e w 4 number of p.I278T mutation carriers found in some populations (Gaustadnes, et al., 1999; Refsum, et al., 2004) .
To date, more than 150 different CBS mutations have been found worldwide, some of them common. Mutation p.I278T is considered panethnic and is particularly frequent in Northern Europe (Janosik, et al., 2001b; Kraus, et al., 1999; Moat, et al., 2004) . In Ireland, the p.G307S mutation accounts for 71% of the mutant alleles (Gallagher, et al., 1995) , and in the Iberian Peninsula and Colombia, mutation p.T191M represents between 40% and 75% (Urreizti, et al., 2006a ) of the mutant alleles.
A truncated form of the human CBS enzyme lacking the C-terminal regulatory domain has been crystallized (Janosik, et al., 2001a; Meier, et al., 2001 ) and structurally characterized (Banerjee and Zou, 2005; Kabil, et al., 2001; Kery, et al., 1999; Meier, et al., 2001; Taoka, et al., 2002) . The active form of this cytoplasmic enzyme is a homotetramer of four 63-KDa subunits. Each subunit combines one heme group and one pyridoxal phosphate (PLP), the latter acting as a cofactor in the reaction. In addition, each subunit binds the allosteric activator S-AdenosilMethionine (S-AdoMet or SAM), an intermediate in the methionine cycle.
Heterologous expression in E. coli has been widely used to test the functionality of the CBS mutant alleles independently from the patient's genetic background (de Franchis, et al., 1994; Katsushima, et al., 2006; Maclean, et al., 2002) . It has been proven to be a useful tool since the E. coli-expressed human CBS is indistinguishable from that obtained from cultured fibroblasts (Bukovska, et al., 1994; Kozich and Kraus, 1992) . In addition, in vitro, its relative activity in response to PLP and SAM is comparable to that of the enzyme obtained from human tissues (Bukovska, et al., 1994; Kozich and Kraus, 1992) . This study updates the CBS mutation spectrum of the homocystinuric patients from the Iberian Peninsula by presenting the analysis of 16 new cases. It also includes one Norwegian, one Indian and four Argentinian patients. In this cohort of 22 cases, 22 mutations were found, ten of which were novel. The new mutations include a deletion of 794 bp (c.532-37_736+438del794) detected by Southern blot analysis and an intronic deletion that leads to the skipping of exon 6, which was characterized using a minigene strategy. The pathogenic role of seven of the changes was assessed by heterologous expression of these mutant proteins, and their stability and activity were analyzed.
Materials And Methods

Patients
Twenty-six patients with classical homocystinuria from 22 unrelated pedigrees were involved in this study. Patients were initially diagnosed by their physicians on the basis of clinical manifestations suggestive of homozygous CBS deficiency.
Biochemically, these patients presented with a combination of severe hyperhomocysteinemia (typically above 150 µmol/l), and hypermethioninemia (typically above 40 µmol/l). Thirteen Spanish, three Portuguese, one Norwegian, one Indian and four Argentinian patients were included in the study. Our research was conducted in accordance with the tenets of the Declaration of Helsinki. The nature and possible consequences of the study were first explained to all patients and/or their parents, before their informed consent for inclusion in the research project was obtained.
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John Wiley & Sons, Inc. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 were amplified by PCR and sequenced as described previously (Urreizti, et al., 2006a ) with some modifications. Briefly, PCR reactions were performed on a final volume of 50 µl with 50 ng gDNA, 0.2 mM of each dNTP, 0.4 mM of each primer, 1.5-2.5 mM MgCl2 and 1.25 U of GoTaq ® Flexi DNA Polymerase (Promega, Madison, WI, USA). All mutations detected were confirmed by restriction analysis of the PCR products with the appropriate restriction enzyme, and the presence of all new mutations was assessed in 100 control chromosomes from Spanish anonymous donors. Primer sequences and PCR conditions have been described previously (Urreizti, et al., 2006a) . MTHFR c.677C>T (rs1801133) was analyzed in all patients as described in Frosst et al. (Frosst, et al., 1995) .
Human Mutation
To characterize the deletion found in patient 87, genomic DNAs of the patient and her parents were PCR-amplified using primers 4F and 7R as described above with the addition of a final concentration of 5% DMSO. The PCR fragments were purified and sequenced.
For naming the mutations the following reference sequences were used:
Genomic, GenBank NG_008938.1; cDNA, ENST00000352178. Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation codon in the reference sequence, according to journal guidelines (www.hgvs.org/mutnomen). The initiation codon is codon 1. 1A ).
Probe design, preparation and hybridization
Four probes were designed by selecting one unique sequence of approximately 600 bp within each restriction fragment. The sequences were aligned to the whole genome by BLAST, to confirm their specificity. These four sequences were PCRamplified from total genomic DNA (as described above), cloned into pUC19 vector (Fermentas, Burlington, ON, Canada) and sequenced. Probes were obtained from the clones by using digoxigenin-dUTP and the "PCR DIG Probe Synthesis Kit" (Roche, Mannheim, Germany), according to the manufacturer's instructions. Primer sequences for the probes are available on request. Labelled probes were subsequently purified using Illustra TM GFX TM PCR DNA and a Gel Band Purification Kit (GE Healthcare, Waukesha, WI, USA).
All subsequent steps of the Southern protocol (prehybridization, hybridization and developing of the filters) were performed using reagents (Dig Easy Hyb) and protocols (Dig Application Manual) from Roche (Mannheim, Germany). All CBS mutant constructs were derived from the wild-type CBS expression plasmid pHCS3 (Kozich and Kraus, 1992) , a gift from the authors of that study. Each mutation was introduced into the wild-type expression plasmid using a Quik
Change II XL TM Site-Directed Mutagenesis Kit (Stratagene Cloning Systems, La Jolla, CA, USA) and expressed in XL-Gold E. coli cells as described in Urreizti et al. (Urreizti, et al., 2006b ). Expression of pHCS3 was used as a positive control, and that of the empty vector pKK388.1 was included as a negative control. Protein extracts were obtained and CBS activity was measured as described in Kraus (Kraus, 1987) with some modifications (Urreizti, et al., 2006b ).
CBS protein analysis
To assess the presence and relative amount of wild-type and mutant CBS proteins, Western blot analysis of the soluble fraction of the crude cell lysates was performed under denaturing conditions as described in Janosik et al. (Janosik, et al., 2001b) , with some modifications (Urreizti, et al., 2006b) .
Minigene construction and splicing assay
Genomic DNA from patient 68a (heterozygote for mutation c.667-14_-7del8) was amplified using CBS primers 4F and 6R to obtain a fragment of 626 or 618 bp (from the last 29 bp of intron 3 to the first 103 bp of intron 6). This PCR product, containing both wild-type and mutant alleles, was purified using Illustra TM GFX TM PCR amplification of each cDNA product was performed using primers T7 and SP6 as previously described (Diaz-Font, et al., 2005; Santamaria, et al., 2008) . The PCR products were electrophoresed and each band of interest was purified and analyzed by sequencing. After sequencing the complete CBS coding sequence, only mutation c.1566delG
Results
Screening for CBS mutations
was found in heterozygosis in patient 87, which she inherited from her father. A Southern blot analysis of this patient and her mother, hybridized with a set of four probes covering the entire CBS genomic region (Fig. 1A) , revealed the same pattern of bands observed in control samples but the relative intensities of fragments 2, 3 and 4 were altered (Fig. 1B) . Hybridization of the same membrane separately with each individual probe revealed an additional band of nearly 10 kb detected by probes B and C (Fig. 1C) . This result was consistent with a deletion removing the DrdI site present in intron 5. To test this hypothesis, a PCR amplification from intron 3 to intron 7 was performed. As shown in Fig. 1D , a new band of 1176 bp was observed in the samples of the patient and her mother. Sequencing revealed a 796-bp deletion (c.532-37_736+438del794), which spans from the last 37 bp of intron 4 to the first 438 bp of intron 6 (Fig. 1E ). This deletion causes a frameshift starting from a valine to glycine substitution at position 178 and leading to a stop codon at residue 201 (p.V178GfsX23).
Analyses of pathogenicity of mutant CBS enzymes
None of the new mutations found was present in 100 control chromosomes, ruling out the possibility of common polymorphisms. We assessed the pathogenicity of all five new missense mutations and of the novel in-frame deletion p.M173del using an E. coli heterologous expression system followed by Western blot and in vitro enzyme activity analysis (Fig. 2) . Mutation p.P49L, previously described by de Franchis et al. (de Franchis, et al., 1998) was also analyzed.
All the proteins from the mutant alleles were found in amounts similar to those of the wild type (Fig. 2, upper panel) . The activity of these mutant enzymes was assayed in vitro, either in the presence or absence of the cofactor PLP, or in the joint presence of PLP and SAM (Fig. 2 , lower panel). As previously described (Kluijtmans, et al., 1996; Maclean, et al., 2002) , we found that the wild-type CBS activity was strongly stimulated by both PLP and the combination of PLP and SAM. Mutations p.M173del, p.I278S, p.D281N and p.D321V showed null activity, either in the absence or presence of the activators. In contrast, mutations p.49L, p.P200L and p.A446S retained different amounts of activity and also the ability to be stimulated.
In particular, mutation p.P49L displayed null activity in the absence of any of the activators, retained 71% of the wild-type activity in the presence of PLP and showed reduced activation by SAM. In contrast, in the absence of any of the activators, mutation p.P200L displayed around a third of the activity of the wild type (15% versus 43%) and retained the ability to be induced by PLP and SAM. SAM stimulation was 2-fold, comparable to that of the wild type. Finally, p.A446S displayed highly variable levels of activity in different tests, in the absence or presence of activators, but in general the values where in the range of the wild type or higher. The small deletion c.667-14_-7del8 involved intron 5 sequences within the acceptor site, without affecting the conserved AG dinucleotide. Since no RNA was available from patients with this mutation (68a and 68b), a minigene assay was performed to test the effect of this mutation on RNA splicing (Fig. 3A) . The genomic region spanning from the 3' part of intron 3 to the 5' part of intron 6 of the CBS gene of the mutant and wild-type alleles was PCR-amplified and cloned within intron 7 of a construct containing several GLB1 exons (see Material and Methods for details).
Effect of a small intronic deletion on RNA splicing
Wild-type and mutant constructs were transfected into HeLa cells and splicing was assayed by RT-PCR using the T7 and SP6 primers (Fig. 3B) . The major band observed in the wild-type sample corresponds to the inclusion of all three CBS exons, whereas in the mutant, exon 6 was skipped, as assessed by sequencing of all the bands.
Discussion
Mutation p.T191M was identified in 21.8% of the alleles of the Spanish and Portuguese patients included in this study (Table 2) . Taking into consideration all 50 homocystinuric patients from the Iberian Peninsula included in this and in our previous studies (Urreizti, et al., 2003; 2006a) , mutation p.T191M accounts for 44% of the mutant chromosomes. Mutation c.1566delG is the second most prevalent change (7% overall), and is particularly common in Portugal (21%). In the present study, we found the panethnic mutation p.I278T for the first time in two unrelated Spanish patients, both in the heterozygote state, and in a Norwegian patient, in homozygosis (Table 2) . Missense mutations are the most common alterations in the CBS gene in the patients of the present study (73%). We also found six deletions of different sizes
(1 bp to 794 bp), five of them novel. plasma methionine (700 µM) and total homocysteine (145 µM). She has been on a normal diet and treated with pyridoxal, folate and betaine since her birth. Currently aged 4 years, her plasma homocysteine and methionine levels are 76 µM and 302 µM, respectively, and she is clinically asymptomatic, highlighting the importance of an early diagnosis.
An intronic 8-bp deletion (c.667-14_-7del8) was found in two siblings (# 68a-# 68b, Table 2 ). Prediction algorithms indicated a subtle reduction in the score of the splicing acceptor site of intron 5. However, a mini-gene analysis clearly showed that it led to the skipping of exon 6, and produced a frameshift. This is consistent with the severity of the patients' phenotypes. We also found a 5 bp deletion in exon 8 in patient # 109, and a 1 bp deletion in exon 6 in patient # 89, both in homozygosis ( Table   2 ). The severity of these genotypes is in accordance with the severe clinical presentation of both patients. In general, frameshift-generating deletions correlate with a more consistently severe phenotype, as expected.
Seven mutations (six missense and a 3-bp deletion) were expressed in E. coli and analyzed by Western blot under denaturing conditions (Fig. 2, upper panel) .
Their presence in amounts similar to those of the wild-type CBS suggests that the mutations do not affect protein integrity. Alternatively, they may affect the catalytic core, proper protein folding or the ability to form tetramers. In this regard, several authors have studied the involvement of certain chaperones in the rescue of missense CBS mutants, and demonstrated that the regulation of these chaperones could lead to almost complete recovery of the mutant protein activity (Kopecka, et al., 2010; Majtan, et al., 2010; Singh, et al., 2007; Singh, et al., 2010 respectively, all in the heterozygous state. In these cases, a correlation between their residual activity and the mild phenotype of the patients was observed.
We found the activity of p.P49L to be 75% of that in the wild type. While our work was ongoing, Kozich et al. (Kozich, et al., 2010) published an analysis of mutation p.P49L expressed in E. coli. They found it to be an active enzyme, indistinguishable from the wild type. Mutation p.P49L was found in two siblings, one with adult onset and the other asymptomatic. Genetic analysis of the proband (# 80a in Table 2 and subject II.1 in Fig. 4) , showed compound heterozygosity for p.P49L and p.R125Q (Table 2) 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r P e e r R e v i e w 15 homocystinuria and had given birth to three healthy offspring without complications. As the two CBS mutations were inherited separately by the offspring, we know that they were not in cis in the mother or in his affected brother. Mutation p.R125Q, the other mutation in family # 80, was originally described as a null activity mutation (Sebastio, et al., 1995) . In their recent publications, Kozich et al. (Kozich, et al., 2010) and Majtan et al. (Majtan, et al., 2010) expressed it in E. coli. In both studies the reduced activity was improved under permissive conditions or in the presence of chaperones. Taken together, these new results on p.P49L and p.R125Q help explain the mild or null affectation of patients # 80a and # 80b. In addition, the MTHFR 677C>T polymorphism may act as a phenotype modifier in this family. However, the discrepancy between the blood markers and the phenotype of patient # 80b remains unexplained.
Mutation p.P200L was identified as the sole mutation in patient # 79. The patient's symptoms are limited to hypertension and severe hyperhomocysteinemia (183 µM), which does not respond to vitamin B6 and folate treatment. A second CBS mutation may be deep intronic, located in a regulatory region far from the gene, or involved in a complex rearrangement not detected by our screening methods.
Mutation p.A446S was found in a mildly affected patient (# 90, Table 2 ), in compound heterozygosis with the null mutation p.D321V (Fig. 2) . The activity of p.A446S was very similar to that of the wild type and this correlates with the mild phenotype of the patient, who only presented with lens dislocation at 45 years, despite a high tHcy level (105 µM, which was reduced to 40 µM after two months of treatment with folic acid and vitamins B6 and B12).
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